[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"empagliflozin-in-cardiorenal-syndrome-type-1\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:empagliflozin-in-cardiorenal-syndrome-type-1":45},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":12,"acronym":13,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":5},"100518461",false,"NCT06030843","The Treatment Effects of Empagliflozin on Renal Outcomes in Cardiorenal Syndrome Type 1","TREAT-CRS","Inclusion criteria\n\n* Age 18 years or more\n* Hospitalized for the primary diagnosis of acute denovo or decompensated chronic heart regardless of ejection fraction\n* AKI KDIGO any stage or urine NGAL ≥ 150 ng\u002FmL\n* Must be able to be enrolled into the trial ≤ 12 hours of diagnosis of AKI or elevated urine NGAL\n\nExclusion criteria\n\n* Denied to participate in the study\n* Cardiogenic shock or unstable hemodynamic (systolic blood pressure of at least 100 mmHg or required inotropic support within last 24 hours)\n* Cardiac mechanical support (i.e. extracorporeal membrane oxygenation and intra-aortic balloon pump)\n* Acute coronary syndrome\n* Diagnosed with cause of AKI other than cardiorenal syndrome (eg. sepsis, nephrotoxic, dehydration)\n* Anuria or requiring dialysis or expected to required dialysis within 24 hr\n* Baseline eGFR ≤ 20 ml\u002Fmin\u002F1.73m2 with or without dialysis initiated\n* Heart or kidney transplanted\n* Previously received any SGLT2i in the last 3 months before admission\n* Allergic to any SGLT2i\n* Type 1 diabetes mellitus\n* History of ketoacidosis, including diabetic ketoacidosis\n* Pregnancy\n* Comorbid conditions with an expected survival of less than 1 months such as end-stage liver or heart disease, or uncurable malignancy","ALL","18 Years",{"count":18,"type":19},200,"ESTIMATED","INTERVENTIONAL",[22,23],"PHASE2","PHASE3","Effects of Empagliflozin compared with placebo in cardiorenal syndrome type 1, evaluated by MAKE30.",[26],"Empagliflozin in Cardiorenal Syndrome Type 1",[28,29,30,31,32],"Empagliflozin","SGLT2i","Cardiorenal syndrome","ADHF","AKI","RECRUITING","2026-06-15",{"date":36,"type":37},"2026-06-16","ACTUAL",{"date":39,"type":37},"2025-03-01",{"date":41,"type":19},"2026-12-31",{"name":43,"class":44},"Chulalongkorn University","OTHER",""]